Aspire-Lakewood Holdings, Inc. ASBP
Aspire-Lakewood Holdings, Inc. (Nasdaq: ASBP) is a cardio-renal-metabolic life-science company. Its next catalyst on record is High-dose sublingual aspirin: Next pharmacodynamic clinical trial (about 32 healthy volunteers) (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: High-dose sublingual aspirin — Next pharmacodynamic clinical trial (about 32 healthy volunteers) (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| High-dose sublingual aspirin (505(b)(2)) | Suspected acute myocardial infarction | small molecule | Phase 1 |
| Sublingual alprazolam, clopidogrel, meclizine, ondansetron, nicotine, ED product | — | small molecule | Pre-clinical |
| Buzz Bomb sublingual caffeine supplement | Dietary supplement (marketed, not FDA-approved drug) | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.